1 |
Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: Clinical and quality-of-life issues. Mayo Clin. Proc. 81: 3-11 (2006)
DOI
ScienceOn
|
2 |
Vlassara H, Stricker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end-products induce glomerular sclerosis and albuminuria in normal rats. P. Natl. Acad. Sci. USA 91: 11704-11708 (1994)
|
3 |
Pacher P, Szabo C. Role of poly (ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: Endothelial dysfunction, as a common underlying theme. Antioxid. Redox. Sign. 7: 1568-1580 (2004)
DOI
ScienceOn
|
4 |
Ii S, Ohta M, Kudo E, Yamaoka T, Tachikawa T. Redox statedependent and sorbitol accumulation-independent diabetic albuminuria in mice with transgene-derived human aldose reductase and sorbitol dehydrogenase deficiency. Diabetologia 47: 541-544 (2004)
DOI
ScienceOn
|
5 |
Takeuchi M, Kikuchi S, Sasaki N, Suzuki T, Watai T, Iwaki Bucala R, Yamagishi S. Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease. Curr. Alzheimer Res. 1: 39-46 (2004)
DOI
ScienceOn
|
6 |
Lusis AJ. Atherosclerosis. Nature 407: 233-241 (2000)
DOI
ScienceOn
|
7 |
Nawroth PP, Bierhaus A, Vogel GE, Hofmann MA, Zumbach M, Wahl P, Ziegler R. Non-enzymaticglycation and oxidative stress in chronic illness and diabetes mellitus. Med. Klin. 94: 29-38 (1999)
|
8 |
Rumble JR, Cooper ME, Soulis-Liparota T, Cox A, Wu L. Vascular hypertrophy in experimental diabetes: Role of advanced glycation end-products. J. Clin. Invest. 99: 1016-1027 (1997)
DOI
ScienceOn
|
9 |
Yan SD, Schmidt AM, Anderson MG, Zhang J, Brett J. Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding proteins. J. Biol. Chem. 269: 9889-9897 (1994)
|
10 |
Galle J, Lenhmann-Bodem C, Hubner U, Heinloth A, Wanner C. CyA and OxLDL cause endothelial dysfunction in isolated arteries through endothelinmediated stimulation of O(2)(-) formation. Nephrol. Dial. Transpl. 15: 339-346 (2000)
DOI
ScienceOn
|
11 |
Schleicher E, Friess U. Oxidative stress, AGE, and atherosclerosis. Kidney Int. Suppl. 106: 17-26 (2007)
|
12 |
Matsuzawa-Nagata N, Takamura T, Ando H, Nakamura S, Kurita S, Misu H, Ota T, Yokoyama M, Honda M, Miyamoto K, Kaneko S. Increased oxidative stress precedes the onset of high-fat dietinduced insulin resistance and obesity. Metabolism 57: 1071-1077 (2008)
DOI
ScienceOn
|
13 |
Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57: 1446-1454 (2008)
DOI
ScienceOn
|
14 |
Ha H, Lee HB. Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney. Nephrology 10: 7-10 (2005)
DOI
ScienceOn
|
15 |
Munzel T, Heitzer T, Harrison DG. The physiology and pathophysiology of the nitric oxide/superoxide anions. Herz 22: 158-172 (1997)
DOI
ScienceOn
|
16 |
Flyvberg A, Denner L, Schrijvers B, Tilton RG, Mogensen TH, Paludan SR. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 53: 166-172 (2004)
DOI
|
17 |
Jensen IJ, Denner I, Schrijers BF, Tilton RG, Rash R, Flyvgerg A. Renal effects of a neutralizing RAGE-antibody in long-term streptozotocin-diabetic mice. J. Endocrinol. 188: 493-501 (2006)
DOI
ScienceOn
|
18 |
Booth AA, Khalifah RG, Todd P, Hudson BG. In vitro kinetics studies of formation of antigenic advanced glycation end products (AGEs). J. Biol. Chem. 272: 5387-5430 (1997)
|
19 |
Voziyan PA, Hudson BG. Pyridoxamine: The many virtues of a maillard reaction inhibitor. Ann. NY Acad. Sci. 1043: 807-816 (2005)
DOI
ScienceOn
|
20 |
Vasan S, Foiles P, Founds H. Therapeutic potential odd breakers of advanced glycation end product-protein cross links. Arch. Biochem. Biophys. 419: 89-96 (2003)
DOI
ScienceOn
|
21 |
Voziyan PA, Metz TO, Baynes JW, HudsonBG. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J. Biol. Chem. 277: 3397-3403 (2002)
DOI
ScienceOn
|
22 |
Vasan S, Zhang X, Karpurniotu A, Bernhagen J, Teichberg S. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382: 211-212 (1996)
DOI
|
23 |
Evans E, Patry R. Management of gestational diabetes mellitus and pharmacists' role in patient education. Am. J. Health-Syst. Ph. 61: 1460-1465 (2004)
|
24 |
Hammes HP, Du X, Edelstein D, Taguchi T, Matsumara T, Ju Q. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 9: 294-299 (2003)
DOI
ScienceOn
|
25 |
Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end-products: Implication for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler. Thromb. 14: 1521-1527 (1994)
DOI
|
26 |
Goova MT, Li J, Kislinger T, Qu W, Lu Y, Bucciarelli LG. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am. J. Pathol. 159: 513-525 (2001)
DOI
ScienceOn
|
27 |
Price DL, Rhett PM, Thorpe SR, Baynes JW, Chelating activity of advanced glycation end-product inhibitors. J. Biol. Chem. 276: 48967-48972 (2001)
DOI
ScienceOn
|
28 |
Williamson JR, Chang K, Frangos M, HasanKS, Ido Y, Kawamura T, Nyengaard JR, Enden M, Kilo C, Tilton RG. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42: 801-813 (1993)
DOI
ScienceOn
|
29 |
Galle J, Schneider R, Winner B, Lehmann-Boden C, Schinzel R. Glyco-oxidized LDL impair endothelial function more potently than oxidized LDL: Role of enhanced oxidative stress. Atherosclerosis 138: 65-77 (1998)
DOI
ScienceOn
|
30 |
Donato R. RAGE: A single receptor for several ligands and different cellular responses: The case of certain S100 proteins. Curr. Mol. Med. 7: 711-724 (2007)
DOI
ScienceOn
|
31 |
Palm F. Intrarenal oxygen in diabetes and a possible link to diabetic nephropathy. Clin. Exp. Pharmacol. P. 33: 997-1001 (2006)
DOI
ScienceOn
|
32 |
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820 (2001)
DOI
ScienceOn
|
33 |
Goldin A, Joshua AB, Schmidt AM, Creager MA. Advanced glycation end products sparking the development of diabetic vascular injury. Circulation 114: 597-605 (2006)
DOI
ScienceOn
|
34 |
Pieper GM, Dondlinger LA. Plasma and vascular tissue arginine are decreased in diabetes: Acute arginine supplementation restores endotheliumdependent relaxation by augmenting cGMP. J. Pharmacol. Exp. Ther. 283: 684-691 (1997)
|
35 |
Thornalley PJ, Yurek-George A, Argirov AK. Kinetics and mechanism of the reaction of aminoguanidine with alphaoxaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem. Pharmacol. 60: 55-65 (2000)
DOI
ScienceOn
|
36 |
Chen XM, Kitts DD. Determining conditions for nitric oxide synthesis in Caco-2 cells using Taguchi and factorial experimental designs. Anal. Biochem. 381: 185-192 (2008)
DOI
ScienceOn
|
37 |
Bakris GL, Bank AJ, Kass DA, Neutel JM, Preston RA, Oparil S. Advanced glycation end-product cross-link breakers: A novel approach to cardiovascular pathologies related to the aging process. Am. J. Hypertens.17: 23-30 (2004)
|
38 |
Somoza V. Five years of research on health risks and benefits of Maillard reaction products: An update. Mol. Nutr. Food Res. 49: 663-672 (2005)
DOI
ScienceOn
|
39 |
Abebe W, MacLeod KM. Protein kinase C-mediated contractile responses of arteries from diabetic rats. Brit. J. Pharmacol. 101: 465-471 (1990)
DOI
ScienceOn
|
40 |
Takeuchi M, Makita Z, Yanagisawa K, Kameda Y, Koike T. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol. Med. 5: 393-405 (1999)
|
41 |
Babei-jadidi R, Karachalian N, Ahmed N, Battab S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52: 2110-2120 (2003)
DOI
ScienceOn
|
42 |
Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S, Takeuchi M. Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen. 21: 197-208 (2006)
DOI
ScienceOn
|
43 |
Kakkar R, Mantha SV, Kalra J, Prasad K. Time course study of oxidative stress in aorta and heart of diabetic rats. Clin. Sci. 91: 441-448 (1996)
DOI
|
44 |
Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. Pyrodoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. J. Biol. Chem. 275: 21177-21184 (2000)
DOI
ScienceOn
|
45 |
Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. Ne-(carboxymethyl) lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10878 (1995)
DOI
ScienceOn
|
46 |
Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB for the ACTIONI Investigator Group. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol. 24: 32-40 (2004)
DOI
ScienceOn
|
47 |
Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interactions with AGE receptors in vascular disease and diabetes mellitus: AGE concept. Cardiovasc. Res. 37: 586-600 (1998)
DOI
ScienceOn
|
48 |
Hein G, Wiegand R, Lehmann G, Stein G, Franke S. Advanced glycation end-products pentosidine and N-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology 42: 1242-1246 (2003)
DOI
ScienceOn
|
49 |
Peyroux J, Sternberg M. Advanced glycation endproducts (AGEs): Pharmacological inhibition in diabetes. Pathol. Biol. 54: 405-419 (2006)
DOI
ScienceOn
|
50 |
Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC. The effect of alagebrium chloride (ALT 711), a novel glucose crosslink breaker, in treatment of elderly patients with diastolic heart failure. J. Card. Fail. 11: 191-195 (2005)
DOI
ScienceOn
|
51 |
Yamagishi S, Nakamura K, Matsui T. Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy. Curr. Drug. Discov. Technol. 3: 83-88 (2006)
DOI
ScienceOn
|
52 |
Jang DS, Kim JM, Lee YM, Kim YS, Kim JH, Kim JS. Puerariafuran, a new inhibitor of advanced glycation end products (AGEs) isolated from the roots of Pueraria lobata. Chem. Pharm. Bull. 54: 1315-1317 (2006)
DOI
ScienceOn
|
53 |
Misawa S, Kuwabara S, Kanai K, Tamura N, Nakata M, Sawai S, Yagui K, Hattori T. Aldose reductase inhibition alters nodal currents and nerve conduction in human diabetics. Neurology 66: 1545-1549 (2006)
DOI
ScienceOn
|
54 |
Miyata T, Yamamoto M, Izuhara Y. From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy. Ann. NY Acad. Sci. 1043: 740-749 (2005)
DOI
ScienceOn
|
55 |
Legan E. Effects of streptozotocin-induced hyperglycemia on agonist-stimulated phosphoinositol turnover in rat aorta. Life Sci. 45: 371-378 (1989)
DOI
ScienceOn
|
56 |
Hill MA, Ege EA. Active and passive mechanical properties of isolated arterioles from STZ-induced diabetic rats: Effect of aminoguanidine treatment. Diabetes 43: 1450-1456 (1994)
DOI
ScienceOn
|
57 |
Wang YK, Hong YJ, Huang ZQ. Protective effects of silybin on human umbilical vein endothelial cell injury induced by in vitro. Vasc. Pharmacol. 43: 198-206 (2005)
DOI
ScienceOn
|
58 |
Weissman AJ. Intensive diabetes treatment and cardiovascular disease. New Engl. J. Med. 354: 1751-1752 (2006)
DOI
|
59 |
Chappey O, Dosquet C, Wautier MP, Wautier JL. Advanced glycation end-products, oxidant stress, and vascular lesions. Eur. J. Clin. Invest. 27: 97-108 (1997)
DOI
ScienceOn
|
60 |
Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch. Biochem. Biophys. 419: 31-40 (2003)
DOI
ScienceOn
|
61 |
Suzuki D, Miyata T, Saotome N, Horie K, Inagi R. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesion. J. Am. Soc. Nephrol. 10: 822-832 (1999)
|
62 |
Service FJ, Rizza RA, Daube JR, O'Brian PC, Dyck PJ. Near normoglycaemia improved nerve conduction and vibration in diabetic neuropathy. Diabetologia 28: 722-727 (1985)
|
63 |
Voziyan PA, Khalifah RG, Thibaudeau C, Yildiz A, Jacob J, Seriani S. Modification of proteins in vitro by physiological levels of glucose. J. Biol. Chem. 278: 46616-46624 (2003)
DOI
ScienceOn
|
64 |
Yang S, Litchfield JE, Baynes JW. AGE-breakers cleave model compounds but not break Maillard crosslinks in skin and tail collagen from diabetic rats. Arch. Biochem. Biophys. 412: 42-46 (2003)
DOI
ScienceOn
|
65 |
Sarti C, Gallagher J. The metabolic syndrome: Prevalence, CHD risk, and treatment. J. Diabetes Complicat. 20: 121-132 (2006)
DOI
ScienceOn
|
66 |
Xu Y, He Z, King GL. Introduction of hyperglycemia and dyslipidemia in the pathogenesis of diabetic vascular complications. Curr. Diab. Rep. 5: 91-97 (2005)
DOI
ScienceOn
|
67 |
Zeng J, Dunlop RA, Rodgers KJ, Davies MJ. Evidence for inactivation of cysteine proteases by reactive carbonyls via glycation of active site thiols. Biochem. J. 398: 197-206 (2006)
DOI
ScienceOn
|
68 |
Odetti P, Aragno I, Rolandi R, Garibaldi S, Valentini S. Scanning force microscopy reveals structural alterations in diabetic rat collagen fibrils: Role of protein glycation. Diabetes Metab. 16: 74-81 (2000)
DOI
ScienceOn
|
69 |
Wirasathien L, Pengsuparp T, Suttisri R, Ueda H, Moriyasu M, Kawanishi K. Inhibitors of aldose reductase and advanced glycation end-products formation from the leaves of Stelechocarpus cauliflorus R.E. Fr. Phytomedicine 14: 546-550 (2007)
DOI
ScienceOn
|
70 |
Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, Schleicher ED. High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J. Clin. Invest. 101: 160-169 (1998)
DOI
ScienceOn
|
71 |
Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T, Jadoui M. Accumulation of carbonyls accelerates the formation of pentosidine, advanced glycation end product: Carbonyl stress in uremia. J. Am. Soc. Nephrol. 9: 2349-2356 (1998)
|
72 |
Figarola JL, Scott S, Loera S, Xi B, Synold T, Weiss I. Prevention of early renal disease, dyslipidemia, and lipid peroxidation in STZ-diabetic rats by LR-9 and LR-74 novel AGE inhibitors. Diabetes Metab. Res. 21: 533-544 (2005)
DOI
ScienceOn
|
73 |
Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New Engl. J. Med. 329: 304-309 (1993)
DOI
ScienceOn
|